Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative Ileus

PHASE2CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

July 9, 2019

Primary Completion Date

July 22, 2020

Study Completion Date

August 8, 2020

Conditions
Ileus
Interventions
DRUG

LB1148

A total of 700 mL of LB1148 will be administered orally as a split dose before surgery.

DRUG

Placebo

A total of 700 mL of placebo will be administered orally as a split dose before surgery.

Trial Locations (6)

Unknown

The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou

General Hospital of Xuzhou Mining Group, Xuzhou

Affiliated Hospital of Jiangsu University, Zhenjiang

The Affiliated Hospital of Qingdao University, Qingdao

Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai

Ningbo First Hospital, Ningbo

All Listed Sponsors
lead

Newsoara Biopharma Co., Ltd.

INDUSTRY

NCT05056935 - Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative Ileus | Biotech Hunter | Biotech Hunter